Eugene Hong, MD
Radiation Oncology · Newark, OHNPI 1811230600
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $554 of the $658 with a category attached, or 84.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $351 and has fallen 57.6% since, to $149 in 2025.
Across 18 payments — averaging $36.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$120
- Siemens Medical Solutions USA, Inc.$104
- Daiichi Sankyo Inc.$100
- Sanofi$80
- AstraZeneca$55
- Tactile Systems Technology Inc$40
- plus $160 from 8 others
What the payments were for
- Food & beverage$55484%
- Education$10416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $120 |
| Siemens Medical Solutions USA, Inc. | 1 | $104 |
| Daiichi Sankyo Inc. | 1 | $100 |
| Sanofi | 1 | $80 |
| AstraZeneca | 2 | $55 |
| Tactile Systems Technology Inc | 1 | $40 |
| AbbVie | 1 | $34 |
| GSK | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Bioprotect Medical, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $19 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Travere Therapeutics, Inc. | 3 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$658 in reported general payments places this provider in the 60th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 30 | $540 |
| Hydrocortisone | 38 | $500 |
| Nystatin | 18 | $371 |
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $193 |
| Prednisone | 16 | $104 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Newark
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
- Gerald SokolCleveland$61K
- Peter FriedFairfield$45K
- Rahul TendulkarCleveland$26K
- Sujith BaligaColumbus$26K
- Anthony ParavatiKettering$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.